Healthcare & Life Sciences M&A: Optimism for 2024
BY Darron Gill, Advisory Partner, Healthcare, Houston AND Britni Barsness, Advisory Director, Financial Due Diligence Here we are again with the dawn of a new year, and questions regarding what 2024 will bring for dealmakers in healthcare and life sciences (HCLS) are front and center in the minds of many. At KPMG, we are happy to present our thoughts around these questions in our 2024 HCLS Investment Outlook (the Outlook). The Outlook is published annually...